IN8BIO, INC. Logo

IN8BIO, INC.

Clinical-stage biopharma developing gamma-delta T cell therapies for cancer.

INAB | US

Overview

Corporate Details

ISIN(s):
US45674E1091
LEI:
Country:
United States of America
Address:
EMPIRE STATE BUILDING, 10118 NEW YORK

Description

IN8BIO, INC. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for solid and hematological tumors. The company's proprietary DeltEx™ platform utilizes allogeneic, autologous, and genetically modified approaches to develop novel cell therapies. IN8BIO was the first to advance genetically modified gamma-delta T cells into clinical trials. Its lead product candidates include INB-400, a Phase 2 asset for newly diagnosed glioblastoma (GBM), and INB-100, a Phase 1 candidate for patients with leukemia undergoing hematopoietic stem cell transplantation. The company is also advancing a broad portfolio of preclinical programs focused on solid tumors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB

Full Filing History Restricted

Access to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset.

Automate Your Workflow. Get a real-time feed of all IN8BIO, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IN8BIO, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for IN8BIO, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Denali Therapeutics Inc. Logo
Develops therapies for neurodegenerative diseases using a blood-brain barrier platform.
United States of America
DNLI
Dermapharm Holding SE Logo
A manufacturer of patent-free branded pharmaceuticals and healthcare products.
Germany
DMP
Dermata Therapeutics, Inc. Logo
Medical dermatology company developing and commercializing OTC skin care products.
United States of America
DRMA
Design Therapeutics, Inc. Logo
Clinical-stage biopharma developing small molecule therapies for genetic diseases.
United States of America
DSGN
Deutsche Biotech Innovativ AG Logo
Develops therapeutics for serious diseases using innovative blood biomarkers.
Germany
DBI
DEVA HOLDİNG A.Ş. Logo
Develops, produces, and markets human medicines, APIs, and veterinary drugs globally.
Spain
DEVA
Devyser Diagnostics Logo
Develops DNA testing kits for hereditary diseases, oncology, and post-transplant monitoring.
Sweden
DVYSR
DexTech Medical AB Logo
Develops drug candidates for urological oncology, focusing on prostate cancer.
Sweden
DEX
DiaMedica Therapeutics Inc. Logo
Clinical-stage biopharma developing therapies for ischemic and vascular diseases.
United States of America
DMAC
Diamyd Medical AB (publ) Logo
A clinical-stage company developing precision therapies for autoimmune diabetes.
Sweden
DMYD

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.